Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638881 · ClinicalTrials.gov registry record · Phase 2
Magnesium for Peroral Endoscopic Myotomy
A Phase 2 study of Esophageal Spasm, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT04638881: Completed Phase 2 study of Esophageal Spasm, sponsored by Stanford University.
NCT04638881 is a Phase 2 study of Esophageal Spasm that has completed, run by Stanford University. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04638881, a Phase 2 study of Esophageal Spasm, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esophgeal pain as measured by the esophageal symptoms questionnaire, while decreasing perioperative opioid requirements.
Primary Outcome
ESQ score is a validated survey score based on questions evaluating esophageal dysphagia, globus, and reflux. Participants answer 11 questions, each rated on a scale of 1 (Not severe) to 7 (Very severe). Scores were summed for an overall score (range 11 to 77, higher scores indicate more severe dysphagia).
Conditions Studied
Interventions
- DRUG Magnesium sulfate
- DRUG Normal Saline
Study Locations (1)
California
- Stanford Health Care - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 2 |
What the finished NCT04638881 record still lists
NCT04638881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Esophageal Spasm appearing as the primary indexed condition, and to 2 interventions - of which Magnesium sulfate is the first listed.
NCT04638881 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04638881 about?
NCT04638881 is a clinical study titled "Magnesium for Peroral Endoscopic Myotomy". Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esop...
What is the current status of trial NCT04638881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-12-28. Estimated completion is 2023-04-13.
What conditions does trial NCT04638881 study?
This clinical trial studies the following conditions: Esophageal Spasm.
What interventions are being tested in trial NCT04638881?
The interventions under investigation include: Magnesium sulfate (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT04638881?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04638881 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04638881's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI